Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus Cadila begins...

    Zydus Cadila begins phase 2 trial for Saroglitazar Mg to treat NAFLD in women with PCOS

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-24T09:35:39+05:30  |  Updated On 24 Aug 2019 9:35 AM IST
    Zydus Cadila begins phase 2 trial for Saroglitazar Mg to treat NAFLD in women with PCOS

    Research suggests that in women with polycystic ovary syndrome (PCOS), there is increased risk for non-alcoholic fatty liver disease, Zydus Cadila said in a regulatory filing.


    New Delhi: Zydus Cadila on Wednesday said it has initiated phase 2 clinical trial for evaluating the effect of Saroglitazar Mg in the treatment of non-alcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome. The trial is currently recruiting patients across several clinical sites in the United States of America and Mexico.


    Research suggests that in women with polycystic ovary syndrome (PCOS), there is increased risk for non-alcoholic fatty liver disease, Zydus Cadila said in a regulatory filing.


    PCOS affects fertility and also significantly increases metabolic complications, it added.


    Also Read: Zydus Cadila wins USFDA nod for Minocycline Hydrochloride ER tablets to treat acne


    Zydus Group Chairman Pankaj R Patel said the company's research programme aims to bring innovative therapies that make a difference to human lives in keeping with our mission to create healthier communities.


    There is a high prevalence of PCOS in the general population affecting 1 in 10 women of childbearing age, causing infrequent or prolonged menstrual periods or excess male hormone.


    "There are currently no treatments approved by the US Food and Drug Administration (USFDA) for treatment of NAFLD," Zydus Cadila said.


    Also Read: Zydus Cadila completes phase III trial of Diabetes drug Lipaglyn in India

    fatty liver diseasemale hormonemetabolicNAFLDPankaj R PatelPCOSpharmapharma companypharma newsphase 2 clinical trialpolycystic ovary syndromeSaroglitazar MgUS Food and Drug AdministrationUSFDAZydus Cadila
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok